Anna C Pavlick
Sandra and Edward Meyer Cancer Center at Weill Cornell Medicine · NYU MEDICAL CENTER
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Anna C Pavlick as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 01:57 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT05583708 · Phase II Study of Peptide Receptor Radionuclide Therapy in Combination With Immunotherapy for Patients With Merkel Cell CancerWeill Medical College of Cornell University · recruiting · Merkel Cell Carcinoma · principal investigator
- Ph1NCT00409383 · Abraxane and Temodar Plus Genasense in Advanced MelanomaGenta Incorporated · unknown · Melanoma · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 01:57 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 3 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 01:57 UTC. The ranking covers the 200 most relevant of 43 PubMed records, and a shared surname and initials can bring in a namesake. All 43 on PubMed
- Nivolumab and ipilimumab versus ipilimumab in untreated melanoma.N Engl J Med · 20152,291 citationsRCR 67.7
- Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib.N Engl J Med · 20121,765 citationsRCR 46.2
- Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial.Lancet Oncol · 20151,309 citationsRCR 40.1
- Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain.N Engl J Med · 20181,088 citationsRCR 35.8
- 776 citationsRCR 20.0
- 774 citationsRCR 23.4
- 667 citationsRCR 16.5
- MHC proteins confer differential sensitivity to CTLA-4 and PD-1 blockade in untreated metastatic melanoma.Sci Transl Med · 2018505 citationsRCR 14.5
- Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group.J Clin Oncol · 2006465 citationsRCR 9.9
- Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor.J Clin Oncol · 2013410 citationsRCR 10.9